Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Repare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare Conference


Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15 at 10:15 a.m. ET.

A live webcast of the fireside can be accessed in the Investor section of the Company's website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company's website for 30 days following the fireside chat.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol? inhibitor programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.


These press releases may also interest you

at 06:22
SAPIENS TO ANNOUNCE FIRST QUARTER OF 2024 FINANCIAL RESULTS ON MAY 8, 2024
Sapiens International Corporation , a leading global provider of software solutions for the insurance industry, announced today that it will report its financial results for the first quarter of 2024 on Tuesday, May 8, 2024. Management will host a...

at 06:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points...

at 06:13
Synchrony Reports First Quarter 2024 Results; Company also Announces Quarterly Stock Dividends and Approval of an Incremental $1.0 Billion Share Repurchase Program
Synchrony Financial today announced its first quarter 2024 results for the period ending March 31, 2024. The earnings news release, financial tables and related materials can be found on the company's investor relations website...

at 06:10
Thermo Fisher Scientific to Host Investor Day
Thermo Fisher Scientific Inc. , the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City. The format will feature presentations by members of Thermo Fisher...

at 06:05
Industry Veteran Brent Barcey Joins OSARO as SVP Corporate Development to Fuel Growth in E-commerce Robotics
OSARO, a global leader in machine-learning-enabled robotics for e-commerce, announced the appointment of industry veteran Brent Barcey as senior vice-president of corporate development. Barcey brings 25 years of experience growing global businesses...

at 06:05
Thermo Fisher Scientific Reports First Quarter 2024 Results
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP...

More news about Science and technology...


News published on and distributed by: